Epidemiology of malignant digestive neuroendocrine tumours

European Journal of Endocrinology

Volumn 168, Issue 4, 2013, Pages

  Lepage, C ^a   Bouvier, A M ^a   Faivre, J ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; EARLY DIAGNOSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; MALIGNANT DIGESTIVE NEUROENDOCRINE TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; REVIEW; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION; ANIMAL; ENDOCRINE TUMOR; GASTROINTESTINAL TUMOR;

ANIMALS; ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS;

MLCS; MLOWN;

EID: 84875183923     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0418     Document Type: Review

References (43)

1. Sobin LH, Gospodarowicz M, Wittekind Ch, editors. UICC (International Union Against Cancer). TNM classification of malignant tumours. 7th ed. New York: Wiley-Blackwell. 2009.
2. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 2006 449 395-401. (doi:10.1007/s00428-006-0250-1)
3. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 2007 451 757-762. (doi:10.1007/s00428-007-0452-1)
4. Solcia E, Kloppel G & Sobin LH. Histological typing of endocrine tumours. In International Histological Classification of Tumours, 2nd edn, pp 61-68. Berlin Heidelberg: Springer-Verlag, 2000.
5. World Health Organisation. International Classification of Diseases for Oncology. ICD-03. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. Geneva, Switzerland: World Health Organisation, 2000.
6. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C & Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 2004 53 549-553. (doi:10.1136/gut.2003.026401)
7. Lepage C, Rachet B & Coleman MP. Survival from malignant digestive endocrine tumors in England and Wales: a populationbased study. Gastroenterology 2007 132 899-904. (doi:10.1053/j.gastro.2007.01.006)
8. Niederle MB, Hackl M, Kaserer K & Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine-Related Cancer 2010 17 909-918. (doi:10.1677/ERC-10-0152)
9. Parkin M, Whelan S, Ferlay J, Teppo L & Thomas D. Cancer incidence in five continents. Vol. VIII IARC Scientific Publications No. 155, Lyon France; 2002, IARC.
10. Lepage C, Cottet V, Chauvenet M, Phelip JM, Bedenne L, Faivre J & Bouvier AM. Trends in the incidence and management of biliary tract cancer: a French population-based study. Journal of Hepatology 2004 54 306-310. (doi:10.1016/j.jhep.2010.06.039)
11. InVS F, HCL, service de biostatistiques, ARC: ouvrage collectif. La situation du cancer en France en 2011. Boulogne-Billancourt: INCa, www.e-cancer.fr, 2011.
12. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 2008 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
13. Brenner B, Tang LH, Klimstra DS & Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. Journal of Clinical Oncology 2004 22 2730-2739. (doi:10.1200/JCO.2004.09.075)
14. Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Faivre J & Gatta G. European disparities in malignant digestive endocrine tumours survival. International Journal of Cancer 2010 126 2928-2934. (doi:10.1002/ijc.24698)
15. Levi F, Randimbison L, Franceschi S & La Vecchia C. Descriptive epidemiology of malignant carcinoids in the swiss canton of Vaud. International Journal of Cancer 1993 53 1036-1037. (doi:10.1002/ijc.2910530630)
16. Crocetti E & Paci E. Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. European Journal of Cancer Prevention 2003 12 191-194. (doi:10.1097/00008469-200306000-00004)
17. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P & Ruszniewski P. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998 43 422-427. (doi:10.1136/gut.43.3.422)
18. Shebani KO, Souba WW, Finkelstein DM, Stark PC, Elgadi KM, Tanabe KK & Ott MJ. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Annals of Surgery 1999 229 815-821. (doi:10.1097/00000658- 199906000-00008)
19. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Díaz- Pérez JA, Martínez Del Prado MP, Alonso Orduña V, Sevilla-García I, Villabona-Artero C, Beguiristain-Gómez A, Llanos-Muñoz M et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Annals of Oncology 2012 21 1794-1803. (doi:10.1093/annonc/mdq022)
20. Moertel CG, Weiland LH, Nagorney DM & Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. New England Journal of Medicine 1987 317 1699-1701. (doi:10.1056/NEJM198712313172704)
21. Mullen JT & Savarese DM. Carcinoid tumors of the appendix: a population-based study. Journal of Surgical Oncology 2011 104 41-44. (doi:10.1002/jso.21888)
22. Maire F, Couvelard A, Vullierme MP, Kianmanesh R, O'Toole D, Hammel P, Belghiti J & Ruszniewski P. Primary endocrine tumours of the liver. British Journal of Surgery 2005 92 1255-1260. (doi:10.1002/bjs.5073)
23. Hauso O, Gustafsson BI, Kidd M,Waldum HL, Drozdov I, Chan AK & Modlin IM. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008 113 2655-2664. (doi:10.1002/cncr.23883)
24. Burke AP, Thomas RM, Elsayed AM & Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997 79 1086-1093. (doi:10.1002/(SICI)1097-0142(19970315)79:6<1086:: AIDCNCR5O3.0.CO;2-E)
25. Modlin IM, Lye KD & Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003 97 934-959. (doi:10.1002/cncr.11105)
26. Corleto VD, Panzuto F, Falconi M, Cannizzaro R, Angeletti S, Moretti A, Delle Fave G, Farinati F & Oncology Study Section of the Italian Society of Gastroenterology. Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease 2001 33 217-221. (doi:10.1016/S1590-8658(01)80710-6)
27. Hollett MD, Jeffrey RB Jr, Nino-Murcia M, Jorgensen MJ & Harris DP. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (< or=1.5 cm) malignant hepatic neoplasms. AJR. American Journal of Roentgenology 1995 164 879-884.
28. Dromain C, de Baere T, Baudin E, Galline J, Ducreux M, Boige V, Duvillard P, Laplanche A, Caillet H, Lasser P et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR. American Journal of Roentgenology 2003 180 121-128.
29. Jamar F, Fiasse R, Leners N & Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. Journal of Nuclear Medicine 1995 36 542-549.
30. Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology. American Society of Hematology Education Program. ASH Education Book, 2006 259-265. (doi:10.1182/asheducation-2006.1.259)
31. Gatta G, Capocaccia R, Coleman MP, Gloeckler Ries LA, Hakulinen T, Micheli A, Sant M, Verdecchia A & Berrino F. Toward a comparison of survival in American and European cancer patients. Cancer 2000 89 893-900. (doi:10.1002/1097-0142(20000815)89:4<893::AID-CNCR24O3.0.CO;2-9)
32. Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. Journal of Experimental & Clinical Cancer Research 2003 22 517-530.
33. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML & Taal BG. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Annals of Oncology 2001 12 1295-1300. (doi:10.1023/A:1012272314550)
34. Moertel CG, Kvols LK, O'Connell MJ & Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991 68 227-232. (doi:10.1002/1097-0142(19910715)68:2<227::AID- CNCR2820680202O3.0.CO;2-I)
35. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 501-513. (doi:10.1056/NEJMoa1003825)
36. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 514-523. (doi:10.1056/NEJMoa1009290)
37. Chauvenet M, Lepage C, Jooste V, Cottet V, Faivre J & Bouvier AM. Prevalence of patients with colorectal cancer requiring follow-up or active treatment. European Journal of Cancer 2009 45 1460-1465. (doi:10.1016/j.ejca. 2009.01.012)
38. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of Clinical Oncology 2005 23 70-78. (doi:10.1200/JCO.2005.01.013)
39. Elias D, Sideris L, Liberale G, Ducreux M, Malka D, Lasser P, Duvillard P & Baudin E. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 2005 137 411-416. (doi:10.1016/j.surg.2004.11.007)
40. Kaltsas G, Rockall A, Papadogias D, Reznek R & Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. European Journal of Endocrinology 2004 151 15-27. (doi:10.1530/eje.0. 1510015)
41. Kaltsas GA, Besser GM & Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews 2004 25 458-511. (doi:10.1210/er.2003-0014)
42. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'dorisio TM, Valkema R, Bodei L & Chinol M. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine 2005 46 (Suppl 1) 62S-66S.
43. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL & Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. Journal of Clinical Oncology 2005 23 2754-2762. (doi:10.1200/JCO.2005.08.066)